MX2018015239A - Composiciones que comprenden timolol y un agente antiinflamatorio. - Google Patents

Composiciones que comprenden timolol y un agente antiinflamatorio.

Info

Publication number
MX2018015239A
MX2018015239A MX2018015239A MX2018015239A MX2018015239A MX 2018015239 A MX2018015239 A MX 2018015239A MX 2018015239 A MX2018015239 A MX 2018015239A MX 2018015239 A MX2018015239 A MX 2018015239A MX 2018015239 A MX2018015239 A MX 2018015239A
Authority
MX
Mexico
Prior art keywords
timolol
compositions
inflammatory agent
combinations
rosacea
Prior art date
Application number
MX2018015239A
Other languages
English (en)
Inventor
Godessart Marina Nuria
Tarrason Encuentra Gema
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2018015239A publication Critical patent/MX2018015239A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a combinaciones que comprenden timolol y un compuesto útil para el tratamiento de rosácea seleccionado de ivermectina, metronidazol y praziquantel y al uso de estas combinaciones en el tratamiento tópico de rosácea.
MX2018015239A 2016-06-16 2017-06-15 Composiciones que comprenden timolol y un agente antiinflamatorio. MX2018015239A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382279 2016-06-16
PCT/EP2017/064707 WO2017216309A1 (en) 2016-06-16 2017-06-15 Compositions comprising timolol and an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
MX2018015239A true MX2018015239A (es) 2019-04-15

Family

ID=56148331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015239A MX2018015239A (es) 2016-06-16 2017-06-15 Composiciones que comprenden timolol y un agente antiinflamatorio.

Country Status (14)

Country Link
US (1) US20190231788A1 (es)
EP (1) EP3471719A1 (es)
JP (1) JP2019518045A (es)
KR (1) KR20190018440A (es)
CN (1) CN109475532A (es)
AR (1) AR108793A1 (es)
AU (1) AU2017285258A1 (es)
BR (1) BR112018075983A2 (es)
CA (1) CA3026625A1 (es)
EA (1) EA201990042A1 (es)
MA (1) MA45387A (es)
MX (1) MX2018015239A (es)
TW (1) TW201803569A (es)
WO (1) WO2017216309A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2866567A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
CN101395164A (zh) * 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法

Also Published As

Publication number Publication date
CN109475532A (zh) 2019-03-15
WO2017216309A1 (en) 2017-12-21
CA3026625A1 (en) 2017-12-21
AU2017285258A1 (en) 2019-01-24
EP3471719A1 (en) 2019-04-24
EA201990042A1 (ru) 2019-05-31
BR112018075983A2 (pt) 2019-04-02
TW201803569A (zh) 2018-02-01
MA45387A (fr) 2019-04-24
AR108793A1 (es) 2018-09-26
KR20190018440A (ko) 2019-02-22
JP2019518045A (ja) 2019-06-27
US20190231788A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2023010042A (es) Polinucleotidos moduladores.
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
MX2023008686A (es) Polinucleotidos moduladores.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2023002507A (es) Inhibidores de cd73.
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
PE20180189A1 (es) Composiciones y metodos para el tratamiento de la anemia
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2017007829A (es) Composicion antimicrobiana.
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
AU2017272405A1 (en) Imidazolone compounds as human Neutrophil Elastase inhibitors
NZ788133A (en) Cd73 inhibitors
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
MX2018015239A (es) Composiciones que comprenden timolol y un agente antiinflamatorio.
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.